HYPR · XBRL financial data

Hyperfine financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HYPR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	2,330	2,686*	3,295	3,631	3,643	2,321*	2,137	2,696	3,437	5,293*	3,903	3,904
Cost of goods and services sold	1,206	1,652*	1,941	1,828	1,735	1,495*	1,254	1,368	1,589	2,599*	1,924	1,924
Gross profit	1,124	1,034*	1,354	1,803	1,908	826*	883	1,328	1,848	2,694*	1,979	1,980
Research and development	5,739	5,962*	5,570	5,959	5,865	5,105*	5,037	4,541	4,048	3,825*	3,845	3,865
General and administrative	4,615	4,173*	4,430	4,421	4,510	4,133*	4,208	3,859	4,152	4,034*	4,130	3,907
Total operating expenses	12,883	12,663*	12,004	12,649	12,871	11,591*	11,785	10,923	10,768	10,362*	10,537	10,449
Operating income (loss)	(11,759)	(11,629)*	(10,650)	(10,846)	(10,963)	(10,765)*	(10,902)	(9,595)	(8,920)	(7,668)*	(8,558)	(8,469)
Interest income	1,021	922*	796	675	585	436*	317	239	187	280*	254	272
Interest expense	—	—	—	—	—	—	0	0	—	—	83	533
Other income (expense)	(19)	23*	6	15	52	(61)*	(451)	85	17	12*	5	3
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(10,757)	(10,684)*	(9,848)	(10,156)	(10,326)	(10,390)*	(9,418)	(9,225)	(11,019)	(5,912)*	(8,623)	(9,298)
Earnings per share, basic USD per share	(0.15)	(0.15)*	(0.14)	(0.14)	(0.14)	(0.14)*	(0.12)	(0.12)	(0.14)	(0.06)*	(0.09)	(0.09)
Earnings per share, diluted USD per share	(0.15)	(0.15)*	(0.14)	(0.14)	(0.14)	(0.14)*	(0.12)	(0.12)	(0.14)	(0.06)*	(0.09)	(0.09)
Weighted average shares, basic thousands of shares	71,464	71,725*	71,934	72,041	72,679	72,991*	75,697	78,077	79,029	94,204*	97,695	99,797
Weighted average shares, diluted thousands of shares	71,464	71,725*	71,934	72,041	72,679	72,991*	75,697	78,077	79,029	94,204*	97,695	99,797

Balance sheet

CSV

Fiscal quarters (HYPR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	85,424	75,183	63,204	53,809	45,765	37,645	33,093	25,420	21,564	35,085	40,778	43,458
Accounts receivable	2,437	3,189	5,343	5,368	6,800	5,956	5,330	5,057	4,886	5,254	3,791	4,217
Inventory	6,940	6,582	7,298	7,465	7,044	5,832	4,639	4,882	5,838	7,090	6,327	6,789
Prepaid and other current assets	2,184	2,391	2,950	2,262	2,002	1,900	2,963	2,687	2,726	1,255	2,631	1,899
Total current assets	98,215	88,908	79,690	71,025	64,094	53,710	48,403	40,096	36,903	50,909	56,033	59,241
Property and equipment, net	3,158	2,999	3,706	3,429	3,125	3,122	3,094	3,122	2,745	2,549	2,503	2,262
Right-of-use asset	—	239	194	149	105	341	280	254	186	316	247	178
Total assets	103,064	94,199	85,443	76,610	69,386	58,901	53,377	45,234	41,511	55,262	60,339	62,999
Accounts payable	908	1,214	2,532	2,238	1,404	1,607	2,305	2,971	3,710	4,051	4,552	2,422
Total current liabilities	8,211	8,768	8,767	8,785	9,959	8,729	7,979	7,988	10,168	11,732	10,154	9,629
Long-term debt	—	—	—	—	—	—	—	—	—	0	13,123	13,235
Lease liability, non-current	—	64	17	—	—	78	16	12	0	66	17	0
Total liabilities	9,297	9,800	9,805	9,849	11,064	9,861	10,263	10,108	14,639	14,257	25,978	26,241
Accumulated deficit	(243,038)	(253,722)	(263,570)	(273,726)	(284,052)	(294,442)	(303,860)	(313,085)	(324,104)	(330,016)	(338,639)	(347,937)
Total stockholders' equity	93,767	84,399	75,638	66,761	58,322	49,040	43,114	35,126	26,872	41,005	34,361	36,758
Total liabilities and equity	103,064	94,199	85,443	76,610	69,386	58,901	53,377	45,234	41,511	55,262	60,339	62,999

Cash flows

CSV

Fiscal quarters (HYPR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(10,757)	(10,684)*	(9,848)	(10,156)	(10,326)	(10,390)*	(9,418)	(9,225)	(11,019)	(5,912)*	(8,623)	(9,298)
Stock-based compensation	1,194*	1,288*	1,032	1,174*	1,102*	1,054*	945	547*	617*	692*	647	903*
Net cash from operating activities	(8,721)*	(9,938)*	(12,510)	(9,383)*	(8,517)*	(8,357)*	(9,249)	(7,910)*	(5,582)*	(5,207)*	(9,008)	(7,268)*
Purchases of property and equipment	263*	258*	145	71*	159*	8*	472	520*	130*	63*	242	30*
Net cash from investing activities	(263)*	(258)*	(145)	(71)*	(159)*	(8)*	(472)	(520)*	(130)*	(63)*	(242)	(30)*
Net cash from financing activities	39*	28*	55	59*	851*	54*	5,582	474*	2,164*	19,282*	14,486	10,784*

Compare with peers

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
CapsoVision	not reported	3,643	(8,403)*	50.0M	—	Q2 FY26 10-QJun 30, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Vivos	2,336	36	(740)*	494.2M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Fractyl Health	47,140	not reported	(15,901)*	159.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.